Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09.

Schellens, J H; Planting, A S; van Acker, B A; Loos, W J; de Boer-Dennert, M; van der Burg, M E; Koier, I; Krediet, R T; Stoter, G; Verweij, J

Schellens, J H; Planting, A S; van Acker, B A; Loos, W J; de Boer-Dennert, M; van der Burg, M E; Koier, I; Krediet, R T; Stoter, G; Verweij, J.

Affiliation

Schellens JH; Department of Medical Oncology, Rotterdam Cancer Institute, Dr. Daniel den Hoed Kliniek, The Netherlands.

J Natl Cancer Inst ; 86(12): 906-12, 1994 Jun 15.

Article in En | MEDLINE | ID: mdl-8196081

Subject(s)

Antineoplastic Agents/therapeutic use; Aziridines/therapeutic use; Indolequinones; Indoles/therapeutic use; Adult; Aged; Antineoplastic Agents/adverse effects; Antineoplastic Agents/pharmacokinetics; Aziridines/adverse effects; Aziridines/pharmacokinetics; Aziridines/pharmacology; Female; Humans; Indoles/adverse effects; Indoles/pharmacokinetics; Indoles/pharmacology; Male; Metabolic Clearance Rate; Middle Aged; Proteinuria/chemically induced

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Aziridines / Indolequinones / Indoles / Antineoplastic Agents Type of study: Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: J Natl Cancer Inst Year: 1994 Document type: Article Affiliation country: Netherlands Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links